Editorials

The Role of Natural Killer Cells in Inflammation in Active Adult-onset Still Disease
J.Y. Jung, H.A. Kim .......................................................... 1253

E.F. Morand, V. Golder ...................................................... 1256

Rheumatoid Arthritis

Effects of Sarilumab on RA as Reported by Patients Using the RA Impact of Disease Scale
L. Gossec, V. Strand, C. Proudfoot, et al. .......................... 1259

Characteristics of Circulating Natural Killer Cells and Their Interferon-γ Production in Active Adult-onset Still Disease
Y. Shimojima, D. Kishida, K.I. Ueno, S. Ushiyama, T. Ichikawa, Y. Sekijima .......................................................... 1268

Spondyloarthropathy

Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study
J.D. Reveille, A. Deodhar, P.H. Caldron, et al. ..................... 1277


Psoriatic Arthritis

Association of Physical Activity and Medication with Enthesitis on Ultrasound in PsA
K. Wervers, I. Herrings, J.J. Luime, et al. .................................. 1290

Peritenon Extensor Tendon Inflammation in PsA Is an Enthesitis-related Lesion C. Macia-Villa, S. Falcao, M. Gutierrez, J. Medina, H. Berner Hammer, E. De Miguel .......................................................... 1295

Systemic Lupus Erythematosus

Predictors of Remission and Low Disease Activity State in SLE: Data from a Multiethnic, Multinational Latin American Cohort
M.F. Ugarte-Gil, D. Wojdyla, G.J. Pons-Estel, et al. .............. 1299

Understanding Nonadherence with HCQ Therapy in SLE
L.H. Liu, H.B. Fervier, R. Goldfien, A. Hemmerling, L.J. Herrinton .......................................................... 1309

Systemic Sclerosis

Cyclophosphamide for SSc-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II
E.R. Volkmann, D.P. Tashkin, M. Sim, et al. ........................ 1316

Factors Influencing Raynaud Condition Score Diary Outcomes in SSc
J.D. Pauling, E. Reilly, T. Smith, T.M. Frech .................................................. 1326

Pediatric Rheumatology

Longitudinal Health Status from Early Disease to Adulthood and Associated Prognostic Factors in JIA
A. Tollisen, A.M. Selvaag, A. Aasland, A. Lerdal, B. Flate .......................................................... 1335

Gout

Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis
J.W. Liew, G.C. Gardner .......................................................... 1345

Images in Rheumatology

Koebner Phenomenon in DM after Subcutaneous Methotrexate Injections
P. Couture, C. Bachmeyer, J.B. Montfort .................................................. 1350

Free online via JRheum Full Release option

Contents continued on page xii
OMERACT 2018: International Consensus Conference on Outcome Measures in Rheumatology, Terrigal, Australia, May 2018

Special Interest Groups, Part 2

OMERACT 2018 Modified Patient-reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies
M. Regardt, C.A. Mecoli, J.K. Park, et al .......................... 1351

Pain Measurement in RMD: Where To Go from Here?
Report from a Special Interest Group at OMERACT 2018

Toward a Core Outcome Measurement Set for PMR:
Report from the OMERACT 2018 Special Interest Group

The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis
M.D. Wechalekar, A. Najm, D.J. Veale, V. Strand .......................... 1365

The SPECTRA Collaboration OMERACT Working Group:
Criterion Validity of Joint Space Outcomes with High-resolution Peripheral Quantitative CT
S.L. Manske, S.C. Brunet, S. Finzel, et al .......................... 1369

Advancing Stiffness Measurement in Rheumatic Disease: Report from the Stiffness Special Interest Group at OMERACT 2018

Musculoskeletal Ultrasound in SLE: Systematic Literature Review by the Lupus Task Force of the OMERACT Ultrasound Working Group

OMERACT Definitions for US Pathologies and Elementary Lesions of Rheumatic Disorders
15 Years On

The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments:
The Musculoskeletal US Example
L. Terslev, E. Naredo, H.I. Keen, et al .......................... 1394

Considerations for Evaluating and Recommending Worker Productivity Outcome Measures: An Update from the OMERACT Worker Productivity Group
S.M. Verstappen, D. Lacaille, A. Boonen, et al .......................... 1401

Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group
T. Pickles, R. Alten, M. Boers, et al .......................... 1406

OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions
K. Toupin-April, J.L. Barton, L. Fraenkel, et al .......................... 1409

Updating OMERACT Core Set of Domains for AAV:
Patient Perspective Using the International Classification of Function, Disability, and Health
N. Milman, E. McConville, J.C. Robson, et al .......................... 1415

Correspondence

Abnormal Cardiac Biomarkers in Patients with SLE and No Prior Heart Disease: The Role of Endomyocardial Biopsy
G. De Luca, C. Campochiaro, L. Dagna .......................... 1421

Reply K. Tselios, D.D. Gladman, P. Harvey,
S. Akhtari, J. Su, M.B. Urowitz .......................... 1422

Testing the Model for Predicting Effectiveness of Anakinra in Systemic JIA
S. Ozen, S. Demir, E.D. Batu .......................... 1422

Reply
J. Tibaldi, B. Saccomanno, R. Caorsi, A. Ravelli .......................... 1424

Meetings .......................... vi